BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34130784)

  • 21. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease.
    Zhang R; Lu X; Wang H; You Y; Zhong Z; Zang S; Zhang C; Shi W; Li J; Wu Q; Fang J; Xia L
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):47-55. PubMed ID: 30031936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
    Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
    J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical Efficacy of NOPHO-AML 2004 Regimen for Treatment of Children with Acute Myelocytic Leukemia (Non-M3)].
    Qiu KY; Liao XY; Huang K; Li Y; Weng WJ; Xu HG; Fang JP; Wu RH; Zhou DH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):375-381. PubMed ID: 29665901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
    Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between Early Treatment Response and Prognosis in Children with Acute Lymphoblastic Leukemia].
    Zheng Y; Cai YW; Fu QC; Wang Q; Ji XQ; Cai LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):733-737. PubMed ID: 29950212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.
    Lion T; Haas OA; Harbott J; Bannier E; Ritterbach J; Jankovic M; Fink FM; Stojimirovic A; Herrmann J; Riehm HJ
    Blood; 1992 Jun; 79(12):3325-30. PubMed ID: 1596573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria.
    Gao HQ; Guan XM; Wen XH; Shen YL; Guo YX; Dou Y; Meng Y; Yu J
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Aug; 23(8):835-840. PubMed ID: 34511174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
    Garderet L; Labopin M; Gorin NC; Polge E; Baruchel A; Meloni G; Ortega J; Vossen J; Bunjes D; Leverger G; Blaise D; Ferrant A; Brune M; Dore E; Gadner H; Zintl F; Yaniv I; Dini G; Frassoni F;
    Blood; 2005 Jan; 105(1):405-9. PubMed ID: 15191953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
    Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
    Cai JY; Xue HL; Chen J; Shen SH; Pan C; Wang X; Zhou M; Tang YJ; Gao YJ; Wang JM; Tang JY
    Zhonghua Er Ke Za Zhi; 2016 Jun; 54(6):456-60. PubMed ID: 27256235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.
    Teyssier AC; Lapillonne H; Pasquet M; Ballerini P; Baruchel A; Ducassou S; Fenneteau O; Petit A; Cuccuini W; Ragu C; Preudhomme C; Mercher T; Sirvent N; Leverger G
    Pediatr Hematol Oncol; 2017 Nov; 34(8):425-427. PubMed ID: 29303660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients.
    Zhang W; Dun J; Li H; Liu J; Chen H; Yu H; Xu J; Zhou F; Qiu Y; Hao J; Hu Q; Wu X
    Hematology; 2023 Dec; 28(1):2231731. PubMed ID: 37522469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
    Pratz KW; Jonas BA; Pullarkat V; Recher C; Schuh AC; Thirman MJ; Garcia JS; DiNardo CD; Vorobyev V; Fracchiolla NS; Yeh SP; Jang JH; Ozcan M; Yamamoto K; Illes A; Zhou Y; Dail M; Chyla B; Potluri J; Döhner H
    J Clin Oncol; 2022 Mar; 40(8):855-865. PubMed ID: 34910556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric non-Down's syndrome acute megakaryoblastic leukemia patients in China: A single center's real-world analysis.
    Zhang A; Liu L; Zong S; Chen X; Liu C; Chang L; Chen X; Yang W; Guo Y; Zhang L; Zou Y; Chen Y; Zhang Y; Ruan M; Zhu X
    Front Oncol; 2022; 12():940725. PubMed ID: 36267971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.